Authors:
Jensen, LH
Wessel, I
Moller, M
Nitiss, JL
Sehested, I
Jensen, PB
Citation: Lh. Jensen et al., N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance, FEBS LETTER, 480(2-3), 2000, pp. 201-207
Authors:
Mikkelsen, M
Moller, A
Jensen, LH
Pedersen, A
Harajehi, JB
Pakkenberg, H
Citation: M. Mikkelsen et al., MPTP-induced parkinsonism in minipigs: A behavioral, biochemical, and histological study, NEUROTOX T, 21(2), 1999, pp. 169-175
Authors:
Nielsen, EO
Varming, T
Mathiesen, C
Jensen, LH
Moller, A
Gouliaev, AH
Watjen, F
Drejer, J
Citation: Eo. Nielsen et al., SPD 502: A water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity, J PHARM EXP, 289(3), 1999, pp. 1492-1501
Authors:
Wessel, I
Jensen, LH
Jensen, PB
Falck, J
Rose, A
Roerth, M
Nitiss, JL
Sehested, M
Citation: I. Wessel et al., Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform, CANCER RES, 59(14), 1999, pp. 3442-3450